Clicky

Quince Therapeutics, Inc.(QNCX)

Description: Quince Therapeutics is focused on advancing innovative precision therapeutics targeting debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote more rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Quince’s discovery pipeline is positioned for rapid expansion across multiple skeletal therapeutic indications to address underserved therapeutic areas with major, unmet medical needs, including osteogenesis imperfecta, fractures, spinal fusion, and other severe bone diseases. The company’s lead compound NOV004 is an anabolic peptide engineered to precisely target and concentrate at the bone fracture site, which preclinical studies demonstrate result in rapid increases in bone density, strength, and healing directly at the site of bone fracture. NOV004 is expected to enter Phase 1 clinical studies in 2023 and advance to a lead indication in osteogenesis imperfecta.


Keywords: Disease Organ Systems Rare Diseases Bone Acute Pain Skeletal Disorders Skeletal System Musculoskeletal System Bone Fracture Osteogenesis Imperfecta

Home Page: www.quincetx.com

QNCX Technical Analysis

601 Gateway Blvd
South San Francisco, CA 94080
United States
Phone: 415 910 5717


Officers

Name Title
Dr. Leslie J. Holsinger Ph.D. Consultant
Dr. Dirk Thye M.D. CEO & Director
Mr. Ted Monohon VP of Fin., Principal Financial Officer & Chief Accounting Officer
Ms. Stacy Roughan VP of Corp. Communications & Investor Relations
Ms. Mary Ellen Sillivos VP of HR
Mr. Brendan Hannah M.B.A. Chief Bus. Officer
Dr. Karen L. Smith L.L.M, L.L.M., M.B.A., M.D., PH.D. Chief Medical Officer
Dr. Stewart A. Low Ph.D. Head of Discovery

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.234
Price-to-Sales TTM: 0
IPO Date: 2019-05-09
Fiscal Year End: December
Full Time Employees: 55
Back to stocks